Previous studies of lung cancer primarily aimed to identify driver genes somatically and have revealed a number of oncogenic driver mutations especially in non-small cell lung cancer (NSCLC), consisting of alterations in EGFR, Kirsten rat sarcoma viral oncogene homolog (KRAS), and anaplastic lymphoma kinase (ALK) etc. (12, 13). This evidence concerns the gene ALK and non-small cell lung carcinoma.